Association between quality of life and sun exposure behaviour in patients treated for cutaneous malignant melanoma

Author(s):  
Luise Winkel Idorn ◽  
Pameli Datta ◽  
Jakob Heydenreich ◽  
Peter Alshede Philipsen ◽  
Hans Christian Olsen Wulf
BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Ylva Naeser ◽  
Hildur Helgadottir ◽  
Yvonne Brandberg ◽  
Johan Hansson ◽  
Roger Olofsson Bagge ◽  
...  

Abstract Background The incidence of cutaneous malignant melanoma (CMM) is increasing worldwide. In Sweden, over 4600 cases were diagnosed in 2018. The prognosis after radical surgery varies considerably with tumor stage. In recent years, new treatment options have become available for metastatic CMM. Early onset of treatment seems to improve outcome, which suggests that early detection of recurrent disease should be beneficial. Consequently, in several countries imaging is a part of the routine follow-up program after surgery of high risk CMM. However, imaging has drawbacks, including resources required (costs, personnel, equipment) and the radiation exposure. Furthermore, many patients experience anxiety in waiting for the imaging results and investigations of irrelevant findings is another factor that also could cause worry and lead to decreased quality of life. Hence, the impact of imaging in this setting is important to address and no randomized study has previously been conducted. The Swedish national guidelines stipulate follow-up for 3 years by clinical examinations only. Methods The TRIM study is a prospective randomized multicenter trial evaluating the potential benefit of imaging and blood tests during follow-up after radical surgery for high-risk CMM, compared to clinical examinations only. Primary endpoint is overall survival (OS) at 5 years. Secondary endpoints are survival from diagnosis of relapse and health-related quality of life (HRQoL). Eligible for inclusion are patients radically operated for CMM stage IIB-C or III with sufficient renal function for iv contrast-enhanced CT and who are expected to be fit for treatment in case of recurrence. The planned number of patients is > 1300. Patients are randomized to clinical examinations for 3 years +/− whole-body imaging with CT or FDG-PET/CT and laboratory tests including S100B protein and LDH. This academic study is supported by the Swedish Melanoma Study Group. Discussion This is the first randomized prospective trial on the potential benefit of imaging as a part of the follow-up scheme after radical surgery for high-risk CMM. Results The first patient was recruited in June 2017 and as of April 2020, almost 500 patients had been included at 19 centers in Sweden. Trial registration ClinicalTrials.gov, NCT 03116412. Registered 17 April 2017, https://clinicaltrials.gov/ct2/show/study/NCT03116412


2008 ◽  
Vol 11 (2) ◽  
pp. 259-271 ◽  
Author(s):  
Richard P. Cashin ◽  
Philip Lui ◽  
Márcio Machado ◽  
Michiel E.H. Hemels ◽  
Patricia K. Corey-Lisle ◽  
...  

2006 ◽  
Vol 9 (6) ◽  
pp. A295 ◽  
Author(s):  
M Machado ◽  
R Cashin ◽  
P Lui ◽  
M Hemels ◽  
P Corey-Lisle ◽  
...  

1996 ◽  
Vol 35 (2) ◽  
pp. 149-158 ◽  
Author(s):  
Valgerdur Sigurdardöttir ◽  
Christina Bolund And ◽  
Marianne Sullivan

2021 ◽  
Vol 1 ◽  
pp. 39
Author(s):  
Rasya Dixit

Acne scars affect up to 95% of those suffering from acne and have a significant negative effect on quality of life. It is imperative to complete acne treatment before scar treatment commences. The treatment of the scars begins with the analysis of the skin type, scar type, lifestyle, and sun exposure. Age of the patient, patient expectations, timelines, and budget are important considerations. Treatment of the scars includes release of the subdermal bands with subcision, improvement of the neocollagenosis by causing regular thermal or mechanical microinjury to the dermis, improvement of epidermal pigment, and improvement of skin hydration. Often, multiple treatments and multimodality treatments need to be used to give satisfactory results.


Sign in / Sign up

Export Citation Format

Share Document